Groundbreaking Findings on (Z)-Endoxifen in Breast Cancer Treatment
Atossa Therapeutics, Inc. has recently released exciting insights regarding their investigational drug (Z)-endoxifen, particularly in its application for treating ER+/HER2- breast cancer. A recent analysis indicates that patients receiving (Z)-endoxifen at a dose of 10 mg daily demonstrated remarkable results in a clinical trial, showcasing not only the efficacy of the drug but also its tolerability.
Details of the Clinical Trial
In an extensive study involving 20 participants diagnosed with ER+/HER2- breast cancer, patients were administered (Z)-endoxifen once daily for an extended period. Impressively, the outcomes highlighted that 95% of the women fulfilled over 75% of the treatment protocol, affirming the feasibility of this innovative therapeutic approach. This preliminary analysis, presented at the RISE UP conference, offers a glimpse into the potential for (Z)-endoxifen to play a significant role in breast cancer management.
Impact on Key Biomarkers
The results from the trial are particularly noteworthy. Patients experienced an average reduction of 69% in the Ki-67 biomarker, which is instrumental in gauging the proliferation of cancer cells within tumors. Furthermore, functional tumor volume (FTV) experienced a decline of over 30%, showcasing the ability of (Z)-endoxifen to shrink tumors effectively.
Tolerability of (Z)-Endoxifen
The drug's side effects were predominantly mild, with participants reporting experiences such as hot flushes and fatigue. Notably, there were no circumstances necessitating dose adjustments or discontinuations due to adverse events, which underscores the potential of (Z)-endoxifen as a patient-friendly treatment option.
Expert Opinions and Future Directions
Dr. Steven Quay, CEO of Atossa Therapeutics, expressed optimism regarding the findings, emphasizing the promising trends in reducing tumor markers. He articulated that these results not only symbolize a positive step forward for the company in its mission to assist patients with ER+/HER2- breast cancer but also reinforce the concept of developing effective and tolerable neoadjuvant therapies.
The ongoing I-SPY 2 trial emphasizes investigating novel treatment pathways for individuals at risk of recurrence post-diagnosis. This study sheds light on the need for innovative solutions, as current chemotherapy approaches often yield limited results in certain patient populations.
Innovative Approach to (Z)-Endoxifen
Atossa is actively working on refining the delivery mechanism of (Z)-endoxifen, aiming to bypass gastric acid, which diminishes the drug's effectiveness by converting it to inactive forms. This meticulous process is aimed at ensuring patients receive maximum therapeutic benefit from their treatment.
Expanding Research Horizons
Atossa's ongoing research includes several phase 2 trials examining (Z)-endoxifen alone and in conjunction with other therapies. These studies are pivotal, as they are tailored to understand the comprehensive effectiveness of (Z)-endoxifen across varied patient profiles and treatment strategies.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is deeply committed to developing groundbreaking therapeutic options for oncology, particularly breast cancer. Utilizing advancements with (Z)-endoxifen, the company aims to address significant unmet needs in the current medical landscape. As the research progresses, Atossa remains focused on delivering effective solutions for patients facing challenging diagnoses.
Contact Information
For media inquiries or further information, reach out to Michael Parks, VP of Investor and Public Relations, at 484-356-7105 or via email at michael.parks@atossainc.com.
Frequently Asked Questions
1. What is (Z)-endoxifen, and how does it work?
(Z)-endoxifen is a selective estrogen receptor modulator (SERM) known for its effectiveness in treating estrogen receptor-positive breast cancer by decreasing tumor volume and reducing cell proliferation rates.
2. What were the key findings from the I-SPY 2 trial?
The trial revealed that (Z)-endoxifen resulted in significant reductions in key biomarkers like Ki-67 and functional tumor volume in most participants.
3. How well did patients tolerate (Z)-endoxifen?
Patients tolerated (Z)-endoxifen well, with only mild side effects reported, and there were no dose adjustments or discontinuations required.
4. What future studies is Atossa conducting with (Z)-endoxifen?
Atossa is investigating (Z)-endoxifen in multiple phase 2 trials to assess its effectiveness in diverse patient populations and treatment combinations.
5. How can patients or interested parties learn more about Atossa?
For more information on Atossa Therapeutics and its ongoing research, individuals can visit the company's official website.
